Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1951 2
1952 3
1953 2
1954 1
1955 2
1956 10
1957 2
1960 1
1966 3
1970 1
1971 1
1974 1
1978 2
1980 1
1983 4
1984 1
1986 1
1987 4
1988 1
1989 2
1990 4
1991 1
1992 2
1994 5
1995 2
1996 7
1997 2
1998 3
1999 3
2000 5
2001 4
2002 5
2003 7
2004 3
2005 9
2006 11
2007 12
2008 4
2009 14
2010 7
2011 9
2012 10
2013 11
2014 14
2015 18
2016 12
2017 7
2018 18
2019 14
2020 18
2021 24
2022 32
2023 29
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

352 results

Results by year

Filters applied: . Clear all
Page 1
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G; FIDELIO-DKD Investigators. Bakris GL, et al. N Engl J Med. 2020 Dec 3;383(23):2219-2229. doi: 10.1056/NEJMoa2025845. Epub 2020 Oct 23. N Engl J Med. 2020. PMID: 33264825 Free article. Clinical Trial.
Guillain-Barré syndrome: causes, immunopathogenic mechanisms and treatment.
Jasti AK, Selmi C, Sarmiento-Monroy JC, Vega DA, Anaya JM, Gershwin ME. Jasti AK, et al. Among authors: vega da. Expert Rev Clin Immunol. 2016 Nov;12(11):1175-1189. doi: 10.1080/1744666X.2016.1193006. Epub 2016 Jun 21. Expert Rev Clin Immunol. 2016. PMID: 27292311 Free article. Review.
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.
Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, Baniecki M, Hendrick VM, Damle B, Simón-Campos A, Pypstra R, Rusnak JM; EPIC-HR Investigators. Hammond J, et al. N Engl J Med. 2022 Apr 14;386(15):1397-1408. doi: 10.1056/NEJMoa2118542. Epub 2022 Feb 16. N Engl J Med. 2022. PMID: 35172054 Free PMC article. Clinical Trial.
Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension.
Freeman MW, Halvorsen YD, Marshall W, Pater M, Isaacsohn J, Pearce C, Murphy B, Alp N, Srivastava A, Bhatt DL, Brown MJ; BrigHTN Investigators. Freeman MW, et al. N Engl J Med. 2023 Feb 2;388(5):395-405. doi: 10.1056/NEJMoa2213169. Epub 2022 Nov 7. N Engl J Med. 2023. PMID: 36342143 Clinical Trial.
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.
Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P, Ruilope LM; FIGARO-DKD Investigators. Pitt B, et al. N Engl J Med. 2021 Dec 9;385(24):2252-2263. doi: 10.1056/NEJMoa2110956. Epub 2021 Aug 28. N Engl J Med. 2021. PMID: 34449181 Clinical Trial.
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, Mao H, Zhang S, Ahmad NN, Bunck MC, Benabbad I, Zhang XM; SURMOUNT-2 investigators. Garvey WT, et al. Lancet. 2023 Aug 19;402(10402):613-626. doi: 10.1016/S0140-6736(23)01200-X. Epub 2023 Jun 26. Lancet. 2023. PMID: 37385275 Clinical Trial.
Review and update on non-suicidal self-injury: who, how and why?
Vega D, Sintes A, Fernández M, Puntí J, Soler J, Santamarina P, Soto À, Lara A, Méndez I, Martínez-Giménez R, Romero S, Pascual JC. Vega D, et al. Actas Esp Psiquiatr. 2018 Jul;46(4):146-55. Epub 2018 Jul 1. Actas Esp Psiquiatr. 2018. PMID: 30079928 Free article. Review.
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis.
Rossing P, Anker SD, Filippatos G, Pitt B, Ruilope LM, Birkenfeld AL, McGill JB, Rosas SE, Joseph A, Gebel M, Roberts L, Scheerer MF, Bakris GL, Agarwal R; FIDELIO-DKD and FIGARO-DKD Investigators. Rossing P, et al. Diabetes Care. 2022 Dec 1;45(12):2991-2998. doi: 10.2337/dc22-0294. Diabetes Care. 2022. PMID: 35972218 Free PMC article. Clinical Trial.
Impact of dapagliflozin on cardiac remodelling in patients with chronic heart failure: The DAPA-MODA study.
Pascual-Figal DA, Zamorano JL, Domingo M, Morillas H, Nuñez J, Cobo Marcos M, Riquelme-Pérez A, Teis A, Santas E, Caro-Martinez C, Pinilla JM, Rodriguez-Palomares JF, Dobarro D, Restrepo-Córdoba MA, González-Juanatey JR, Bayés Genís A; DAPA-MODA Study Investigators. Pascual-Figal DA, et al. Eur J Heart Fail. 2023 Aug;25(8):1352-1360. doi: 10.1002/ejhf.2884. Epub 2023 Jun 7. Eur J Heart Fail. 2023. PMID: 37211950
Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis.
Agarwal R, Tu W, Farjat AE, Farag YMK, Toto R, Kaul S, Lawatscheck R, Rohwedder K, Ruilope LM, Rossing P, Pitt B, Filippatos G, Anker SD, Bakris GL; FIDELIO-DKD and FIGARO-DKD Investigators. Agarwal R, et al. Ann Intern Med. 2023 Dec;176(12):1606-1616. doi: 10.7326/M23-1023. Epub 2023 Dec 5. Ann Intern Med. 2023. PMID: 38048573 Clinical Trial.
352 results